G. Dark

Medicine · Health Sciences

17h-index2.0kcitations45works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Ovarian cancer diagnosis and treatment(13), Occupational and environmental lung diseases(8), Pleural and Pulmonary Diseases(7), Intraperitoneal and Appendiceal Malignancies(6), Lung Cancer Treatments and Mutations(5)

Publications45 total

Oncology at a Glance
2025
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial
The Lancet Oncology·2022· 40 citedOpen Access
Participants aux Davidson's Principles and Practice of Medicine, 23eédition
Elsevier eBooks·2022
Objective responses to first-line neoadjuvant carboplatin–paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial
The Lancet Oncology·2020· 56 citedOpen Access
Quality of Life with weekly platinum-based chemotherapy in newly diagnosed Ovarian Cancer: the ICON8 phase III randomised controlled clinical trial
The Lancet Oncology·2020
An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor
Gynecologic Oncology·2019· 98 citedOpen Access
Response to neoadjuvant chemotherapy in ICON8: A GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment
Annals of Oncology·2018· 4 citedOpen Access
Addressing the burden of cancer in East Africa through cascaded training and education by local doctors.
Journal of Clinical Oncology·2018· 1 cited
Oncology
2017
Cell biology
2017
A multicenter, open-label, expanded phase 2 study to evaluate the safety and efficacy of etirinotecan pegol, a polymer conjugate of irinotecan, in women with recurrent platinum-resistant or refractory ovarian cancer
Gynecologic Oncology·2017· 10 citedOpen Access
Impact of a 2-Week Oncology Placement on Medical Students’ Perception of Cancer
Journal of Cancer Education·2016· 9 cited
Multicentre trial of carboplatin/paclitaxel versus oxaliplatin/capecitabine, each with/without bevacizumab, as first line chemotherapy for patients with mucinous epithelial ovarian cancer (mEOC).
Journal of Clinical Oncology·2015· 34 cited
Randomized Multicenter Phase II Trial Comparing Two Schedules of Etirinotecan Pegol (NKTR-102) in Women With Recurrent Platinum-Resistant/Refractory Epithelial Ovarian Cancer
Journal of Clinical Oncology·2013· 52 citedOpen Access
The role of NKTR-102 in women with platinum resistant/refractory ovarian cancer and failure on pegylated liposomal doxorubicin (PLD).
Journal of Clinical Oncology·2011· 6 cited
Phase II study of NKTR-102 in women with platinum-resistant/refractory ovarian cancer.
Journal of Clinical Oncology·2010· 26 cited
Contributors
Elsevier eBooks·2010
Chemotherapy for malignant germ cell ovarian cancer in patients with early stage, advanced and recurrent disease
Cochrane Database of Systematic Reviews·2009
Single-Agent Pemetrexed for Chemonaïve and Pretreated Patients with Malignant Pleural Mesothelioma: Results of an International Expanded Access Program
Journal of Thoracic Oncology·2008· 64 citedOpen Access
Phase II Study of Vinflunine in Malignant Pleural Mesothelioma
Journal of Clinical Oncology·2007· 43 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Rosemary Lord(6), Jonathan A. Ledermann(6), Timothy Perren(5), Gordon Rustin(5), J. Margery(5), J. Blatter(4), Iain A. McNeish(4), Adrian Cook(4), Elizabeth C James(4), Marcia Hall(4), Ignace Vergote(4), John P. Micha(4), Daniel L. Spitz(4), Denis Talbot(4), G Dabouis(4), Rebecca M. Perrett(4), H. G. Taylor(4), Giorgio V. Scagliotti(3), Nicholas Reed(3), Paul Taylor(3)